Breaking News

ProBioGen Licenses GlymaxX Technology to Bayer

Will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncology indications

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

ProBioGen AG, a service and technology provider for complex therapeutic antibodies and glycoproteins, has entered a license agreement with Bayer AG for the  GlymaxX Technology. Under the agreement, Bayer will leverage the technology to further increase the potency of an undisclosed antibody candidate for oncological indications. ProBioGen’s antibody-dependent cellular cytotoxicity (ADCC) enhancing technology GlymaxX will be applied during cell line development. “We are glad to add Bayer to...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters